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INtrODUctION
Gastric cancer is among the most common malignant tumors of the digestive tract [1] . Although the rates of gastric cancer have decreased substantially in most parts of the world, mortality is still high globally, and gastric cancer is ranked fourth in incidence among cancers [2, 3] , particularly in less-developed countries [4] . Eastern Asia has the highest incidence of gastric cancer occurs [2] . In addition to H. pylori infection and poor dietary habits, immune regulation also plays an important role in gastric cancer development, progression, metastasis, and resistance to treatment. Our previous studies found that immunosuppressive cells, especially immunosuppressive regulatory T cells (Tregs), play important roles in tumor escape in gastric cancer [5] [6] [7] .
In addition to Tregs, there is also a discrete subset of B cells, described and confirmed as regulatory B cells (Bregs) [8] [9] [10] . However, there are no specific markers for Bregs [11, 12] [24, 25] and granzyme B + cells [26] , play regulatory roles in human diseases. As there is no agreed consensus regarding the combination of Breg cell-linked markers, various research teams have been identifying Breg cells using a diverse array of markers. As Breg cell function and cell sorting depend on the type and number of markers used, the most appropriate markers for Breg cells in human gastric cancer need confirmation.
Emerging evidence suggests that Bregs play essential roles in inflammation and autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) [27] , systemic lupus erythematosus (SLE) [21] , rheumatoid arthritis (RA) [22] , multiple sclerosis (MS) [28] , inflammatory bowel disease (IBD) [16, 29] , hematological diseases [23, 30] , parasitic infections [31, www.impactjournals.com/oncotarget 32], tuberculosis [20, 33] and graft versus host disease [18, 34] . Although Bregs have been extensively studied in these diseases, there is little knowledge on the role of Bregs in human cancer. It is reported that GrB-expressing B cells (granzyme B + Bregs) reside within the microenvironment of different tumor types [35] . In mice, tumor cells can induce B cells to produce IL-10, which inhibits CD8 + T cells activity and reduces IFN-γ production by CD8 + T and NK cells. IL-10 + Breg deficiency can enhance anti-tumor action [36] , while Bregs evoked by tumor cells (tBregs) inhibit anti-tumor responses and upregulate Tregs, thus facilitating breast cancer metastasis [37] . Tumor metastasis can also be abrogated by the inactivation of tBregs in mice [38] . While experimental models have yielded important insights into the mechanisms by which B cells affect tumor immunity, the role of Bregs in human gastric cancer has not been previously described.
In this study, we quantified CD19 hi Bregs are involved in immunosuppression in gastric cancer via inhibition of anti-tumor helper T cells (Th1 cells) and promotion of pro-tumor Treg cells. To our knowledge, this study is the first to define the role and mechanism of action of Bregs in human gastric cancer.
rEsULts
Increased IL-10-producing breg cells in gastric cancer
As B lymphocyte cells correlate with many significant functions in immune homeostasis [39, 40] , we measured the percentage of CD19 + B cells among CD45 + lymphocytes in peripheral blood from healthy controls (HCs) and gastric cancer patients (GCs) via flow cytometry. There was no statistical difference between HCs and GCs (P > 0.05, Figure 1A ). Lymphocyte infiltration into solid tumors is an important factor in prognosis [40] . Thus, to explore the characteristics of B cells in patients with gastric cancer, the percentage of CD19 + B cells was analyzed in PBMCs, normal tissues, peritumoral tissues and tumor tissues using flow cytometry. When compared with normal tissues or PBMCs, the percentage of CD19 + B cells was higher in peritumoral and tumor tissues (P < 0.001 or P < 0.05, Figure 1B ). Immunohistochemical analyses of CD19 + B cells revealed a large number of B cells in tumor tissues of different TNM stages, suggesting the infiltration of B cells ( Figure 1C , Figure S1A ).
Emerging evidence has shown an increased percentage of IL-10 + Bregs in numerous diseases [9, 41] . IL-10 levels were measured in serum from both HCs and GCs. GCs had increased serum IL-10 as compared to HCs (P < 0.001, Figure 1D ). IL-10-producing B cells were also analyzed in PBMCs from HCs and GCs, the percentage of CD19 + IL-10 + cells of CD19 + B cells was increased in GCs compared to HCs (P < 0.001, Figure 1E ). To further confirm this characteristic in tumor tissues, we performed fluorescence labeling and confocal microscopy analyses of CD19 + IL-10 + B cells were performed in tumors ( Figure  S1B ). IL-10 + B cells were also analyzed in PBMCs, peritumoral tissues, and tumor tissues of gastric cancer patients using flow cytometry. Compared with PBMCs and peritumoral tissues, there was an increase in IL-10-producing Bregs in tumor tissues (P < 0.01 or P < 0.05, Figure 1F ).
characterization of IL-10-producing breg cells in gastric cancer
We next conducted a detailed surface marker analysis of IL-10 + Breg cells. PBMCs from gastric cancer patients were stained with various combinations of monoclonal antibodies to proteins which have been suggested for use in identifying Bregs [12] , including: CD5, CD1d, CD38, CD24, IgM, CD25, CD10, and CD21. Compared with IL-10 -B cells, IL-10 + B cells expressed higher levels of CD5, CD38, CD24 and CD25 (P < 0.001, Figure 2A ). The majority of IL-10 + B cells also expressed higher level of CD1d, IgM and CD10 (P < 0.01, Figure 2A ) and CD21 (P < 0.05, Figure 2A ) when compared to IL-10 -B cells. The differences between IL-10 -and IL-10 + were also compared both in healthy control PBMCs and gastric cancer lesions ( Figure S2A-B) . As CD5/CD1d are regulatory facrors in mouse models of inflammation [14, 41] and CD24/CD38 are involved in human autoimmune diseases [23, 37] , we assessed the expression of these markers in CD19 + B cells via flow cytometry. CD5 cells in PBMCs of HCs and GCs. The percentage of Bregs in GCs was higher than that of HCs (7.5% vs. 5.0%, P < 0.001, Figure 3A) . However, the percentage of Bregs was not correlated with TNM stage ( Figure S3 ). To further understand the relationship among Bregs and other T cell subsets in gastric cancer, the percentages of CD3 Figure 4C ), whereas non-Bregs did not significantly inhibit the production of IFN-γ or TNF-α secretion (NS, Figure 4C) . Moreover, addition of anti-IL-10 antibody inhibited Bregs from suppressing the secrection of IFN-γ and TNF-α ( Figure S5A) .
We T cells compared to non-depleted PBMCs from the same individuals (P < 0.05, Figure 4D ). Depletion of non-Bregs did not promote the expression of IFN-γ and TNF-α by CD4 + T cells (NS, Figure 4D ). PBMCs from HCs were also showed an increased percentage of IFN-γ and TNF-α with Breg depletion compared with non- 
bregs convert effector t cells into FoxP3-expressing tregs
As already shown, there was a significant positive correlation between Bregs and Tregs in gastric cancer ( Figure 3E ). We therefore hypothesized that there might be an interaction between CD19 
CD25
-effector T cells from GCs were co-cultured with autologous Bregs or nonBregs. There was a higher increase in FoxP3 expression in CD4 + CD25 -T cells co-cultured with Bregs than in those cultured with non-Bregs or controls (P < 0.05, P < 0.01, respectively Figure 5B ). As it was previously reported that Bregs lack suppressive capacity in autoimmune diseases [21, 22] , to further determine whether the regulatory properties of Bregs differ between HCs and GCs, sorted CD4 
CD38
hi Bregs produce IL-10. To determine whether IL-10 was involved in the conversion of T cells to Tregs, cells were treated with anti-IL-10 neutralizing monoclonal antibody (mAb) and isotype control. T cell conversion was not effectively inhibited by the neutralization of IL-10 (NS, Figure 6A ). As TGF-β was widely believed to be a highly important factor in the development of Tregs, we next quantified TGF-β mRNA in sorted CD19 
low/-B cell subsets from HCs using real-time PCR. Bregs had high TGF-β mRNA expression (P < 0.05, P < 0.01, Figure 6B an increase in TGF-β1 expression in Bregs (P < 0.05, P < 0.01, Figure 6C) .
We then quantified the percentage of TGF-β1 positive cells in Bregs and the two B cell subsets from GCs. As found in HC cells, there was an increased percentage of TGF-β1 in Bregs from GCs ( Figure 6D ). Moreover, there was a higher percentage of TGF-β1 positive cells in Bregs from GCs than in HCs (25.2±6.73% vs. 15.5±6.78%, P < 0.05, Figure 6E ). To further determine the role of TGF-β1 during T cell conversion, CD24 hi CD38 hi Bregs were cocultured with CD4 +
CD25
-effector T cells and incubated with anti-TGF-β1 neutralizing mAb. T cell conversion was abolished by the addition of TGF-β1 mAb (from 3.85±1.08% to 2.25±0.68%, P < 0.01, Figure 6F ). These results suggest T cell conversion to CD4 
DIscUssION
Bregs play a key role in inflammation, autoimmune diseases, and other inflammatory disease [9, 16, 18, [20] [21] [22] [23] [27] [28] [29] [30] [31] [32] [33] [34] . However, little is known about the potential roles of Bregs in the development of human tumors. We are the first to investigate the characterization of Bregs in human gastric cancer and reveal their possible roles and mechanisms of action. In this study, we determined that increased CD19 As shown in previous studies, there is no consensus regarding the most appropriate combination of Breg-linked markers, and therefore different research teams have used diverse surface and intracellular markers of regulatory B cells [13-21, 24, 25, 37] . Approximately 21 biomarkers in mouse and human Breg cells [12] and some other markers in murine tumor models [42] have been reviewed. However, Breg cell function and cell sorting analysis depend on the type and number of markers used; therefore, the most appropriate markers for Bregs in human gastric cancer had to be confirmed first. Although there are still no specific markers or unique nuclear transcription factors for Bregs, emerging evidence has suggested that IL-10 is the defining trait of Bregs [9, 41] . Our results demonstrate that CD19
hi B cell subsets possess a robust immune regulatory capacity to produce IL-10 in gastric cancer, which is consistent with a previous report in SLE and includes most CD5 + CD1d hi B cells [21] . Our results also support the immunoregulatory phenotypes of Bregs www.impactjournals.com/oncotarget in both mice models and humans reported previously. Our phenotypic research on Bregs in gastric cancer may provide important data for defining Bregs and provide a reference for use in research on human tumors.
In our study, we detected significantly increased CD19
hi Bregs in gastric cancer patients. The enhanced percentage of Bregs may invole in effector immune responses and could have a significant impact on the development of gastric cancer. As we all know, CD4 + Th cells are essential to the immune response of anti-tumor and Th1 cells [43, 44] , a predominant Th cell subtype characterized by IFN-γ and TNF-α secretion. We showed that there is no noticeable inhibition of CD3 + T cells or CD4 + Th cells proliferation by Bregs, which is consistent with a previous report in mice [45] and MS patients [28] . Although Bregs did not suppress the expansion of T cells in vitro, their roles in cytokine production cannot be ruled out. We observed that Bregs from gastric cancer do inhibit the production of IFN-γ and TNF-α. However, inconsistent with our present results, it has been reported that Bregs failed to suppress CD4 + T cell cytokine production in SLE [21] . Perhaps some functions of Bregs are impaired in autoimmune diseases.
As our previous studies reported an enhanced frequency of Tregs in gastric cancer [5] [6] [7] -effector T cells into CD4 + FoxP3 + Tregs, which are dependent on TGF-β1 in gastric cancer. Our results are in contrast with another study in RA, which showed that Bregs could not promote Treg conversion in RA patients [22] . This functional discrepancy of Breg cells may be attributed to the different diseases states. In addition, due to the lack of consistent markers for Bregs, the cells identified as Bregs in other studies, both in vitro and in mouse model systems, may not represent the same cell types, which could also explain the discrepancies.
Collectively, our results suggest that Breg cells might be involved in gastric cancer immune escape, promoting cancer progression. The enhanced suppressive capacity of Bregs in gastric cancer disturbs the balance of the tumor-protective and tumor-promoting functions. This acceleration of tumor progression accelerating function was also recently reported in Bregs from hepatocellular carcinoma [50] . Importantly, all of our functional studies were conducted with Bregs in peripheral blood from healthy controls or gastric cancer patients. The function of Bregs from tumor tissues was not examined because the MFI of CD24 was decreased in IL-10 + B cells, less than in IL-10 -B cells from tumor (P < 0.05, Figure S2B ) and few CD24 hi CD38 hi Bregs were detected in tumor tissues ( Figure  S6) , as confirmed by newly published research [51] .
Collectively, as summarized in Figure 7 , our findings demonstrate that regulatory B cells are important for gastric cancer immune escape by suppressing the generation of IFN-γ and TNF-α from CD4 + Th cells and producing TGF-β1 to promote regulatory T cell conversion. These actions of Bregs, all of which impair the anti-tumor response, promote immune escape in the 
MAtErIALs AND MEtHODs
Patients and controls
Patients with gastric cancer (N = 107, 25 females and 82 males, mean age = 65.6 years, age range from 33 to 84 years) without previous treatments were enrolled in the study upon giving informed consent. According to the TNM classification for gastric cancer (International Union Against Cancer, UICC) (2010, 7 th edition), the patients were divided into four stages (Supplementary Table 1 ). Closely age-matched, healthy subjects (N = 45, 16 male and 29 females, mean age = 63.6 years, age range from 35 to 80 years) were recruited as healthy controls. Tumor tissues, peritumoral tissues (at least 2 cm distant from the tumor site) and normal tissues (at least 4 cm distant from the tumor site) were obtained intraoperatively from 45 patients. This study was approved by the ethical committee of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
cell preparation
Cell preparation was performed as described in the Supplementary Information.
Multicolor flow cytometry analysis
The following antibodies were used: anti-human CD19, CD21, CD38, TBNK 6-Color Kit and isotype controls (BD Biosciences), CD24, CD1d, IL-10, FoxP3 (eBiosciences), CD3, CD4, CD5, CD10, CD22, CD25, CD45, IFN-γ, TNF-α, IL-4 and isotype controls (all from Beckman Coulter), IgM (DAKO) , TGF-β1 and isotype controls (Biolegend). Cell staining and flow cytometry analysis were performed according to routine laboratory methods, as described in the Supplementary Information. Stained cells were analyzed via flow cytometry analysis using a FACS Canto II (BD Biosciences). Data were analyzed using FlowJo software (Tree Star, Ashland, OR). 
co-culture and neutralization assay of bregs
Cell co-culture and flow cytometry analysis were performed as described in the Supplementary Information. The neutralization of anti-IL-10 antibody (R&D, final concentration of 5 μg/ml) and isotype control antibody (R&D, mouse IgG2B) or anti-TGF-β1 neutralizing antibody (R&D, final concentration of 4 μg/ ml) and isotype control antibody (R&D, mouse IgG1) was performed during co-culture experiment.
Immunohistochemistry and confocal microscopy analysis
Tumor tissues and peritumoral tissues were obtained intraoperatively from 45 patients. Immunohistochemical staining and immunofluorescence were performed as previously described [35] . Details are described in the Supplementary Information. 
RNA extraction and real-time PCR
CD38
low/-B subset cells were sorted, and total RNA was extracted from the sorting B cell subsets using RNA Extracting mini Kits (Qiagen). After RT-PCR (Takara), real-Time PCR (Takara) was performed according to kit instructions. Relative expression was determined using the 2 -ΔΔCt method with averaged relative levels of GAPDH used for normalization. The sequences of primers are listed in Supplementary Table 2 .
cytokine detection via ELIsA assay
Serum from healthy controls and gastric cancer patients was stored at -80 o C. Serum IL-10 levels in healthy control and gastric cancer patients were measured using a commercially available ELISA system (R&D) following the instructions of the manufactures. The reactions were quantified via spectrophotometry using a microplate reader (SYNERGY2, BioTek, USA). www.impactjournals.com/oncotarget statistical analysis All data are shown as mean ± SD. Statistical analyses were performed with GraphPad Prism 5.0 using linear regression, t test (Paired t test or Mann-Whitney Test, two groups) or two-way ANOVA for all comparisons described in the study, and differences were considered significant at P < 0.05 (*P < 0.05, **P < 0.01 and ***P < 0.001).
